This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sereinig, S.
Right arrow Articles by Egorov, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sereinig, S.
Right arrow Articles by Egorov, A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, August 2006, p. 898-904, Vol. 13, No. 8
1071-412X/06/$08.00+0     doi:10.1128/CVI.00056-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Influenza Virus NS Vectors Expressing the Mycobacterium tuberculosis ESAT-6 Protein Induce CD4+ Th1 Immune Response and Protect Animals against Tuberculosis Challenge

Sabine Sereinig,1,{dagger}* Marina Stukova,2,{dagger} Natalia Zabolotnyh,3 Boris Ferko,1 Christian Kittel,1 Julia Romanova,1 Tatiana Vinogradova,3 Hermann Katinger,1 Oleg Kiselev,2 and Andrej Egorov1,2

Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria,1 Influenza Research Institute, Russian Academy of Medical Science, Prof. Popova Str. 15/17, 196376 St. Petersburg, Russia,2 Saint-Petersburg Research Institute of Phthisiopulmonology, Ligowsky 2-4, 193036 St. Petersburg, Russia3

Received 8 February 2006/ Returned for modification 27 March 2006/ Accepted 10 May 2006

Infection with Mycobacterium tuberculosis remains a major cause of morbidity and mortality all over the world. Since the effectiveness of the only available tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is suboptimal, there is a strong demand to develop new tuberculosis vaccines. As tuberculosis is an airborne disease, the intranasal route of vaccination might be preferable. Live influenza virus vaccines might be considered as potential vectors for mucosal immunization against various viral or bacterial pathogens, including M. tuberculosis. We generated several subtypes of attenuated recombinant influenza A viruses expressing the 6-kDa early secretory antigenic target protein (ESAT-6) of M. tuberculosis from the NS1 reading frame. We were able to demonstrate the potency of influenza virus NS vectors to induce an M. tuberculosis-specific Th1 immune response in mice. Moreover, intranasal immunization of mice and guinea pigs with such vectors induced protection against mycobacterial challenge, similar to that induced by BCG vaccination.

* Corresponding author. Mailing address: Institute of Applied Microbiology, Muthgasse 18, 1190 Vienna, Austria. Phone: 43 1 36006-6804. Fax: 43 1 3697615. E-mail: S.Sereinig{at}iam.boku.ac.at.

{dagger} S.S. and M.S. contributed equally to this study.

Clinical and Vaccine Immunology, August 2006, p. 898-904, Vol. 13, No. 8
1071-412X/06/$08.00+0     doi:10.1128/CVI.00056-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sexton, A., De Rose, R., Reece, J. C., Alcantara, S., Loh, L., Moffat, J. M., Laurie, K., Hurt, A., Doherty, P. C., Turner, S. J., Kent, S. J., Stambas, J. (2009). Evaluation of Recombinant Influenza Virus-Simian Immunodeficiency Virus Vaccines in Macaques. J. Virol. 83: 7619-7628 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»